Horizon And Arrowhead To Develop RNAi Therapeutic For Gout
Target Is Xanthine Dehydrogenase, Primary Source Of Serum Uric Acid
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.
